Medical Device and Healthcare Industry Trends — April 20, 2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Sky Labs' "CART BP pro" ring-type blood pressure monitor has reaffirmed its technical and clinical viability at the 2026 KSC Spring Conference. BioSolution is strengthening its core pipeline with a three-tier osteoarthritis treatment lineup, nearing clinical approval for its injectable cell therapy. Meanwhile, Seongnam City is calling for local biotech and healthcare companies to join the "MEDICA 2026" exhibition in Germany to support their global expansion.
Medical Device and Healthcare Industry Trends — April 20, 2026
Medical Device Technology and Industry News
Sky Labs' "CART BP pro" Reaffirms Technical Reliability at 2026 KSC
Sky Labs (CEO Lee Byung-hwan) announced on the 20th that the technical reliability and clinical utility of its ring-type blood pressure monitor, "CART BP pro," were reaffirmed at the 2026 Korean Society of Cardiology (KSC) Spring Conference held on the 17th and 18th.
Seongnam City Recruits Companies for "MEDICA 2026" to Boost Global Sales
Seongnam City, Gyeonggi-do, is recruiting companies to participate in "MEDICA 2026," the world’s largest medical device exhibition held in Düsseldorf, Germany, to help local biotech and healthcare firms expand into international markets.
BioSolution Secures Three-Tier Osteoarthritis Lineup; Clinical Approval Expected in First Half
BioSolution is approaching clinical approval for its core pipeline in the first half of the year, with expectations rising for its injectable cell therapy entry into clinical trials. The company is strengthening its pipeline by building a three-tier lineup for osteoarthritis treatment.
Policy and Regulatory Updates
No new policy announcements from the Ministry of Food and Drug Safety (MFDS) were identified within the last 24 hours. However, please refer to the following recent trends:
Hyundai Bioscience Receives Approval to Amend Phase 1 Trial for Prostate Cancer Drug "CP-PCA07"
Hyundai Bioscience announced on the 17th that it received approval to amend its clinical trial plan for its prostate cancer drug candidate "CP-PCA07." This amendment allows for the combined use of the existing drug Enzalutamide and CP-PCA07 for patients with castration-resistant prostate cancer.
GC Biopharma USA Presents Study on Immunoglobulin Aggregation at NHIA 2026
GC Biopharma (CEO Hur Eun-chul) announced on the 17th that its US subsidiary, "GC Biopharma USA," will present research results on the aggregation profile of its intravenous immunoglobulin (IVIG) product at the National Home Infusion Association (NHIA 2026) annual conference.
MFDS Personnel Appointment: Han Woon-seop Promoted to Director General of Imported Food Safety Policy
The Ministry of Food and Drug Safety has conducted a personnel reshuffle, including the promotion of Han Woon-seop to Director General of the Imported Food Safety Policy Bureau.
Clinical Research and Healthcare Trends
Software-Based Devices Dominate Domestic Medical Device Clinical Trials, Reaching Half This Year
The presence of software-based devices in domestic medical device clinical trials is growing rapidly. With diagnostic algorithms, rehabilitation/evaluation software, and digital therapeutics (DTx) emerging as key pillars of clinical trials, the landscape of the medical device development market is shifting.
National Evidence-based Healthcare Collaborating Agency (NECA) Holds 2026 Annual Conference
The National Evidence-based Healthcare Collaborating Agency (President Lee Jae-tae, hereinafter NECA) held its 2026 annual conference on April 7 under the theme, "After Evidence: The New Role of Research and Policy in a Transitional Era." The conference focused on the role of research that goes beyond evidence generation and is actually utilized in policy and medical fields.
Major News in Pharma/Biotech: Hanmi Pharmaceutical Launches Obesity Drug Consultative Body
In the third week of April 2026, the domestic pharma/biotech industry buzzed with news of the launch of an official consultative body for Hanmi Pharmaceutical, which plans to launch its new obesity drug this year.
Summary and Outlook
As of April 20, 2026, the domestic medical device and healthcare industry shows a prominent trend toward securing clinical reliability for wearable medical devices and the rise of Software as a Medical Device (SaMD). Sky Labs' "CART BP pro" reaffirming its clinical value at the KSC indicates that wearable blood pressure monitoring devices are playing an increasingly significant role in medical practice.
According to Medical Times, software-based devices now account for half of all domestic medical device clinical trials, reflecting the rapid growth in digital therapeutics (DTx) and AI diagnostic software.
On the corporate front, BioSolution’s clinical progress with cell therapy and Hyundai Bioscience’s approval for clinical amendment for their prostate cancer drug highlight the efforts of domestic biotech and medical device firms to expand their pipelines. Meanwhile, Seongnam City’s recruitment for "MEDICA 2026" demonstrates active government support for the global expansion of domestic medical device companies.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
